Mibefradil--A New Calcium-Channel Blocker
Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker for treatment of hypertension and chronic stable angina....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Mibefradil--A New Calcium-Channel Blocker
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1013
Article Code: 1013a
Date: November 7, 1997
Volume: 39
Pages: 103-105
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1013
Article Code: 1013a
Date: November 7, 1997
Volume: 39
Pages: 103-105
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)